Citations

Clear

2429 citation(s) found for "Shah, SS".

Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature
Downing, Nicholas S., Cheng, Theresa M., Shah, Nilay D. , Ross, Joseph S. , Cheng, Theresa, Krumholz, Harlan M. , Ross, Joseph S

Mayo Clinic

JAMA Internal Medicine | May 6, 2014 | Volume: 174 | Issue: 7 | Pages: 1176

10.1001/jamainternmed.2014.1371 | PMID 24796406 Get It

Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis
Joshi, Hemant , Subramanian, Indira V., Schnettler, Erica, Rupaimoole, Rajesha , Evans, Colleen, Saluja, Manju, Jing, Yawu, Ivan, Cristina , Shah, Vijay H. , Ramakrishnan, Sundaram , Ghosh, Goutam , Roy, Sabita , Zeng, Yan , Sood, Anil K.

Mayo Clinic

Proceedings of the National Academy of Sciences | March 25, 2014 | Volume: 111 | Issue: 14 | Pages: 5331-5336

10.1073/pnas.1317242111 | PMID 24706848 Get It

Significance Tumor cells adapt to hypoxia by modulating energy production and utilization. Endocytosis is an energy-consuming process that is suppressed during hypoxia. Our studies show that Dynamin 2 (DNM2), a key component of endocytic machinery, is transcriptionally suppressed by HIF-1. Genetic and pharmacological inactivation of DNM2 stabilized HIF-1α and HIF-2α. Furthermore, miR-199a, which is encoded from the opposite strand of DNM2 , exerts reciprocal negative regulation upon HIF-1α and HIF-2α. Overexpression of miR-199a decreased HIF-1α and HIF-2α, cell migration, and metastasis. These findings establish a regulatory loop between endocytic pathway and hypoxic response in tumor cells.
Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?
Zhang, Yuanhui , Mason, Jennifer, Smith, Steven A., Shah, Nilay D. , McCoy, Rozalina G. , Denton, Brian T.

Mayo Clinic

Diabetes Care | February 27, 2014 | Volume: 37 | Issue: 5 | Pages: 1338-1345

10.2337/dc13-1901 | PMID 24574345 Get It

OBJECTIVE While metformin is generally accepted as the first-line agent in treatment of type 2 diabetes, there are insufficient evidence and extensive debate about the best second-line agent. We aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost. RESEARCH DESIGN AND METHODS We developed and validated a new population-based glycemic control Markov model that simulates natural variation in HbA1c progression. The model was calibrated using a U.S. data set of privately insured individuals diagnosed with type 2 diabetes. We compared treatment intensification of metformin monotherapy with sulfonylurea, dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, or insulin. Outcome measures included life-years (LYs), quality-adjusted life-years (QALYs), mean time to insulin dependence, and expected medication cost per QALY from diagnosis to first diabetes complication (ischemic heart disease, myocardial infarction, congestive heart failure, stroke, blindness, renal failure, amputation) or death. RESULTS According to our model, all regimens resulted in similar LYs and QALYs regardless of glycemic control goal, but the regimen with sulfonylurea incurred significantly lower cost per QALY and resulted in the longest time to insulin dependence. An HbA1c goal of 7% (53 mmol/mol) produced higher QALYs compared with a goal of 8% (64 mmol/mol) for all regimens. CONCLUSIONS Use of sulfonylurea as second-line therapy for type 2 diabetes generated glycemic control and QALYs comparable with those associated with other agents but at lower cost. A model that incorporates HbA1c and diabetes complications can serve as a useful clinical decision tool for selection of treatment options.
Association of type of renal surgery and access to robotic technology for kidney cancer: results from a population‐based cohort
Kardos, Steven V., Gross, Cary P. , Shah, Nilay D. , Schulam, Peter G., Trinh, Quoc‐Dien , Smaldone, Marc C. , Sun, Maxine , Weight, Christopher , Sammon, Jesse D. , Han, Leona C., Kim, Simon P. , Trinh, Quoc-Dien

Mayo Clinic

BJU International | February 27, 2014 | Volume: 114 | Issue: 4 | Pages: 549-554

10.1111/bju.12711 | PMID 24571281 Get It

Objective To evaluate the relationship between partial nephrectomy ( PN ) and hospital availability of robot‐assisted surgery from a population‐based cohort in the USA . Methods After merging the Nationwide Inpatient Sample ( NIS ) and the A merican Hospital Association survey from 2006 to 2008, we identified 21 179 patients who underwent either PN or radical nephrectomy ( RN ) for renal cell carcinoma ( RCC ). The primary outcome assessed was the type of nephrectomy performed. Multivariable logistic regression identified the patient and hospital characteristics associated with receipt of PN . Results We identified 4832 (22.8%) and 16 347 (77.2%) patients who were treated for RCC with PN and RN , respectively. On multivariable analysis, patients were more likely to receive PN at academic centres (odds ratio [ OR ] 2.77; P < 0.001), urban centres ( OR 3.66; P < 0.001) and A merican College of Surgeons ( ACOS )‐designated cancer centres ( OR : 1.10; P < 0.05) compared with non‐academic, rural and non‐ ACOS ‐designated cancer centre hospitals, respectively. Robot‐assisted surgery availability at a hospital was also associated with a higher adjusted odds of PN compared with centres without that availability ( OR 1.28; P < 0.001). Conclusions Although academic and urban locations are establi s hed factors that affect the receipt of PN for RCC , the availability of robot‐assisted surgery at a hospital was also independently associated with higher use of PN . Our results are informative in identifying other key hospital characteristics which may facilitate greater adoption of PN .
A Disposable Tear Glucose Biosensor—Part 4
Belle, Jeffrey T. La , Engelschall, Erica, Lan, Kenneth, Shah, Pankti, Saez, Neil , Maxwell, Stephanie, Adamson, Teagan, Abou-Eid, Michelle, McAferty, Kenyon, Patel, Dharmendra, Patel, Dharmendra R., Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | February 11, 2014 | Volume: 8 | Issue: 1 | Pages: 109-116

10.1177/1932296813511741 | PMID 24876546 Get It

Objective: A prototype tear glucose (TG) sensor was tested in New Zealand white rabbits to assess eye irritation, blood glucose (BG) and TG lag time, and correlation with BG. Methods: A total of 4 animals were used. Eye irritation was monitored by Lissamine green dye and analyzed using image analysis software. Lag time was correlated with an oral glucose load while recording TG and BG readings. Correlation between TG and BG were plotted against one another to form a correlation diagram, using a Yellow Springs Instrument (YSI) and self-monitoring of blood glucose as the reference measurements. Finally, TG levels were calculated using analytically derived expressions. Results: From repeated testing carried over the course of 12 months, little to no eye irritation was detected. TG fluctuations over time visually appeared to trace the same pattern as BG with an average lag times of 13 minutes. TG levels calculated from the device current measurements ranged from 4 to 20 mg/dL and correlated linearly with BG levels of 75-160 mg/dL (TG = 0.1723 BG = 7.9448 mg/dL; R 2 = .7544). Conclusion: The first steps were taken toward preliminary development of a sensor for self-monitoring of tear glucose (SMTG). No conjunctival irritation in any of the animals was noted. Lag time between TG and BG was found to be noticeable, but a quantitative modeling to correlate lag time in this study is unnecessary. Measured currents from the sensors and the calculated TG showed promising correlation to BG levels. Previous analytical bench marking showed BG and TG levels consistent with other literature.
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort
Kim, SP, Shah, ND, Weight, Christopher , Thompson, R. H., Moriarty, James P. , Shippee, Nathan D. , Costello, BA, Boorjian, SA, Leibovich, BC, Shippee, Nathan

Mayo Clinic

International braz j urol | February 4, 2014 | Volume: 37 | Issue: 5 | Pages: 663-663

10.1590/s1677-55382011000500018 Get It

Coronary Artery Bypass Grafting Versus Drug-Eluting Stents in Patients with End-Stage Renal Disease
Shah, Ishan K., Lim, Ju Yong , Erwin, Patricia J., Park, Soon J., Deo, Salil V. , Dunlay, Shannon M. , Dillon, John

Mayo Clinic

Journal of Cardiac Surgery | January 22, 2014 | Volume: 29 | Issue: 2 | Pages: 163-169

10.1111/jocs.12296 | PMID 24447133 Get It

Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Downing, Nicholas S., Aminawung, Jenerius A. , Shah, Nilay D. , Ross, Joseph S. , Krumholz, Harlan M. , Ross, Joseph S

Mayo Clinic

JAMA | January 21, 2014 | Volume: 311 | Issue: 4 | Pages: 368

10.1001/jama.2013.282034 | PMID 24449315 Get It

A Disposable Tear Glucose Biosensor—Part 3: Assessment of Enzymatic Specificity
Lan, Kenneth, McAferty, Kenyon, Shah, Pankti, Lieberman, Erica, Patel, Dharmendra, Belle, Jeffrey T. La , Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | January 10, 2014 | Volume: 5 | Issue: 5 | Pages: 1108-1115

10.1177/193229681100500511 | PMID 22027303 Get It

Background: A concept for a tear glucose sensor based on amperometric measurement of enzymatic oxidation of glucose was previously presented, using glucose dehydrogenase flavin adenine dinucleotide (GDH-FAD) as the enzyme. Glucose dehydrogenase flavin adenine dinucleotide is further characterized in this article and evaluated for suitability in glucose-sensing applications in purified tear-like saline, with specific attention to the effect of interfering substances only. These interferents are specifically saccharides that could interact with the enzymatic activity seen in the sensor's performance. Methods: Bench top amperometric glucose assays were performed using an assay solution of GDH-FAD and ferricyanide redox mediator with samples of glucose, mannose, lactose, maltose, galactose, fructose, sucrose, and xylose at varying concentrations to evaluate specificity, linear dynamic range, signal size, and signal-to-noise ratio. A comparison study was done by substituting an equivalent activity unit concentration of glucose oxidase (GOx) for GDH-FAD. Results: Glucose dehydrogenase flavin adenine dinucleotide was found to be more sensitive than GOx, producing larger oxidation currents than GOx on an identical glucose concentration gradient, and GDH-FAD exhibited larger slope response (-5.65 × 10 −7 versus −3.11 × 10 −7 A/mM), signal-to-noise ratio (18.04 versus 2.62), and linear dynamic range (0–30 versus 0–10 mM), and lower background signal (−7.12 versus −261.63 nA) than GOx under the same assay conditions. GDH-FAD responds equally to glucose and xylose but is otherwise specific for glucose. Conclusion: Glucose dehydrogenase flavin adenine dinucleotide compares favorably with GOx in many sensor-relevant attributes and may enable measurement of glucose concentrations both higher and lower than those measurable by GOx. GDH-FAD is a viable enzyme to use in the proposed amperometric tear glucose sensor system and perhaps also in detecting extreme hypoglycemia or hyperglycemia in blood.
Smoking Status and Health Care Costs in the Perioperative Period
Moriarty, James P. , Schroeder, Darrell R. , Shi, Yu , Shah, Nilay D. , Borah, Bijan J. , Moriarty, James, Warner, David O. , Schroeder, Darrell

Mayo Clinic

JAMA Surgery | January 1, 2014 | Volume: 149 | Issue: 3 | Pages: 259

10.1001/jamasurg.2013.5009 | PMID 24382595 Get It